Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Reena, Jatyan"'
Autor:
Nishtha Chaurawal, Charu Misra, Harshita Abul Barkat, Reena Jatyan, Deepak Chitkara, Md. Abul Barkat, Teenu Sharma, Bhupinder Singh, Kaisar Raza
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-15 (2022)
Abstract Sorafenib tosylate (SFB) is a multikinase inhibitor that inhibits tumour growth and proliferation for the management of breast cancer but is also associated with issues like toxicity and drug resistance. Also, being a biopharmaceutical class
Externí odkaz:
https://doaj.org/article/1d336f146a02423097fc23b4f9649348
Autor:
Reena, Jatyan, Prabhjeet, Singh, Deepak Kumar, Sahel, Y G, Karthik, Anupama, Mittal, Deepak, Chitkara
Publikováno v:
Journal of Controlled Release. 350:494-513
Temozolomide (TMZ), an imidazotetrazine, is a second-generation DNA alkylating agent used as a first-line treatment of glioblastoma multiforme (GBM). It was approved by FDA in 2005 and declared a blockbuster drug in 2008. Although TMZ has shown 100%
Autor:
Deepak Kumar Sahel, Sangam Giri Goswami, Reena Jatyan, Anupma Kumari, Anupama Mittal, Sivaprakash Ramalingam, Deepak Chitkara
Publikováno v:
Macromolecular Rapid Communications.
Autor:
Nishtha Chaurawal, Charu Misra, Harshita Abul Barkat, Reena Jatyan, Deepak Chitkara, Md. Abul Barkat, Teenu Sharma, Bhupinder Singh, Kaisar Raza
Publikováno v:
Scientific reports. 12(1)
Sorafenib tosylate (SFB) is a multikinase inhibitor that inhibits tumour growth and proliferation for the management of breast cancer but is also associated with issues like toxicity and drug resistance. Also, being a biopharmaceutical class II (BCS
Publikováno v:
Chemistry and physics of lipids. 236
Instability, poor cellular uptake and unfavorable pharmacokinetics and biodistribution of many therapeutic molecules require modification in their physicochemical properties. The conjugation of these APIs with fatty acids has demonstrated an enhancem